We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Oncology

Oncology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Study Finds Infusion Timing Does Not Affect CAR T-Cell Therapy Outcomes for Large B-Cell Lymphoma
Hematology-OncologyCAR T-cell therapyChronobiology

Study Finds Infusion Timing Does Not Affect CAR T-Cell Therapy Outcomes for Large B-Cell Lymphoma

By MedXY|May 11, 2026

A retrospective study of 584 Australian lymphoma patients shows no significant link between CAR T-cell infusion timing and treatment outcomes, suggesting chronobiology may not influence results in large B-cell lymphoma therapy.

Estrogen Therapy Linked to Improved Survival in Certain Ovarian Cancer Patients Under 60
newssurvival outcomesovarian cancer

Estrogen Therapy Linked to Improved Survival in Certain Ovarian Cancer Patients Under 60

By MedXY|Aug 18, 2026

Study shows post-diagnosis estrogen therapy improves survival in high-grade serous and clear cell ovarian cancers but may worsen outcomes in endometrioid subtypes, offering guidance for managing menopausal symptoms in younger survivors.

A Body Surface Area–Adjusted Bevacizumab Target Was Linked to Better Survival in Atezolizumab-Treated Unresectable Hepatocellular Carcinoma
Gastroenterologyatezolizumabbevacizumab

A Body Surface Area–Adjusted Bevacizumab Target Was Linked to Better Survival in Atezolizumab-Treated Unresectable Hepatocellular Carcinoma

By MedXY|May 10, 2026

A nationwide Japanese real-world study suggests that a defined body surface area–adjusted bevacizumab exposure range may improve progression-free and overall survival in unresectable HCC treated with atezolizumab plus bevacizumab, without i

A Stromal CTHRC1 Biomarker Framework May Identify Colorectal Cancers With Poor Prognosis and Limited Immunotherapy Benefit
Gastroenterologycancer-associated fibroblastscolorectal cancer

A Stromal CTHRC1 Biomarker Framework May Identify Colorectal Cancers With Poor Prognosis and Limited Immunotherapy Benefit

By MedXY|May 10, 2026

A large multiomic colorectal cancer study identifies CTHRC1-positive fibroblasts as a stromal biomarker linked to TGF-beta activity, adverse outcomes, and reduced checkpoint inhibitor benefit across both MSI and MSS disease.

Tumor-Infiltrating Clonal Hematopoiesis Emerges as a Pan-Cancer Prognostic Signal in Solid Tumors
Hematology-OncologyClonal hematopoiesisoverall survival

Tumor-Infiltrating Clonal Hematopoiesis Emerges as a Pan-Cancer Prognostic Signal in Solid Tumors

By MedXY|May 9, 2026

A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast can

Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal Carcinoma
newscancer treatmentchemoradiotherapy

Sustained Locoregional Control With Deintensified Chemoradiotherapy for HPV Oropharyngeal Carcinoma

By MedXY|May 8, 2026

A cohort study demonstrates that reduced-dose 60-Gy chemoradiotherapy effectively maintains locoregional control in HPV-positive oropharyngeal cancer patients while minimizing treatment toxicity, with 5-year survival rates exceeding 92%.

Impact of Immunocompromise on Survival in HPV-Positive Throat Cancer Patients
newsHPVoropharyngeal cancer

Impact of Immunocompromise on Survival in HPV-Positive Throat Cancer Patients

By MedXY|May 8, 2026

This study examines how pre-existing immunocompromise affects survival and outcomes in patients with HPV-positive oropharyngeal cancer treated surgically. Immunocompromised patients showed significantly worse overall survival compared to no

Adherence to Surveillance in the Watch and Wait Approach for Rectal Cancer
Gastroenterologycancer surveillanceNonoperative Management

Adherence to Surveillance in the Watch and Wait Approach for Rectal Cancer

By MedXY|May 8, 2026

Study finds 62% of rectal cancer patients on Watch and Wait receive optimal surveillance, with younger patients showing better adherence. Critical gaps occur in the first year, particularly in initial endoscopic/imaging exams and colonoscop

Rectal Cancer Accreditation Was Linked to Higher Hospital Volume Without More Care Fragmentation
General Surgeryaccreditationhospital volume

Rectal Cancer Accreditation Was Linked to Higher Hospital Volume Without More Care Fragmentation

By MedXY|May 8, 2026

A national difference-in-differences study found NAPRC accreditation was associated with modest growth in rectal cancer volume and stage I procedural volume, without evidence of increased care fragmentation.

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib
newsreal‑world evidenceplatelet monitoring

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib

By MedXY|Aug 18, 2026

A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation

Gut Microbiome Signatures Improve Diagnosis and Prognostic Stratification in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma
Gastroenterologygut microbiomemetagenomics

Gut Microbiome Signatures Improve Diagnosis and Prognostic Stratification in Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

By MedXY|May 7, 2026

A large shotgun metagenomic study links gut dysbiosis to EBV-associated nasopharyngeal carcinoma and shows that microbial markers, especially combined with EBV markers, may strengthen diagnosis and prognostic assessment.

Medicare’s Oncology Care Model Did Not Increase Systemic Therapy Starts and Was Linked to Lower Use in Poor-Prognosis Cancer
newsChăm sóc dựa trên giá trịMedicare

Medicare’s Oncology Care Model Did Not Increase Systemic Therapy Starts and Was Linked to Lower Use in Poor-Prognosis Cancer

By MedXY|May 5, 2026

A matched difference-in-differences study found that the Oncology Care Model did not increase systemic therapy initiation overall and was associated with lower treatment initiation and lower spending in poor-prognosis cancers.

Adding Ipilimumab to Brentuximab Vedotin Plus Nivolumab Did Not Improve Complete Response, but May Prolong Disease Control Without Transplant in Relapsed Hodgkin Lymphoma
Hematology-OncologyBrentuximab vedotinIpilimumab

Adding Ipilimumab to Brentuximab Vedotin Plus Nivolumab Did Not Improve Complete Response, but May Prolong Disease Control Without Transplant in Relapsed Hodgkin Lymphoma

By MedXY|May 4, 2026

In randomized phase 2 E4412, BV/ipilimumab/nivolumab did not significantly improve complete response or overall PFS versus BV/nivolumab, but showed a notable signal for longer disease control among patients who did not undergo stem cell tra

MBD4 Germline Variants Mark a Strong Predisposition to Uveal Melanoma, Supporting Broad Genetic Screening
newsgenetic screeninggermline predisposition

MBD4 Germline Variants Mark a Strong Predisposition to Uveal Melanoma, Supporting Broad Genetic Screening

By MedXY|May 4, 2026

A large French case series found pathogenic or likely pathogenic germline MBD4 variants in 23 of 896 patients with uveal melanoma, corresponding to a 31-fold relative risk versus the general population.

Calcitonin Doubling Rate Sharpens Postoperative Recurrence Risk Stratification in Medullary Thyroid Carcinoma With Biochemical Persistent Disease
Diabetes & Endocrinologybiochemical persistent diseasecalcitonin doubling rate

Calcitonin Doubling Rate Sharpens Postoperative Recurrence Risk Stratification in Medullary Thyroid Carcinoma With Biochemical Persistent Disease

By MedXY|May 4, 2026

In medullary thyroid carcinoma with biochemical persistent disease after surgery, an early postoperative calcitonin doubling rate of at least 0.3/year strongly identified patients at higher recurrence risk and may help tailor surveillance i

Real-World Antibody-Drug Conjugate Outcomes in Gynecologic Cancers Appear Consistent Across Demographic Subgroups
newshealth disparitiesgynecologic cancers

Real-World Antibody-Drug Conjugate Outcomes in Gynecologic Cancers Appear Consistent Across Demographic Subgroups

By MedXY|Aug 18, 2026

In a single-center real-world cohort, survival with mirvetuximab soravtansine, trastuzumab deruxtecan, and tisotumab vedotin broadly mirrored pivotal trials, with no independent survival differences by age, race, or ethnicity after adjustme

Cancer Risk in Familial Adenomatous Polyposis Remains Broad Despite Preventive Surgery: Dutch Nationwide Data Highlight Rising Gastric Cancer Burden
Gastroenterologycancer surveillanceduodenal cancer

Cancer Risk in Familial Adenomatous Polyposis Remains Broad Despite Preventive Surgery: Dutch Nationwide Data Highlight Rising Gastric Cancer Burden

By MedXY|May 3, 2026

A nationwide Dutch cohort confirms that patients with FAP remain at markedly elevated risk for multiple gastrointestinal and extraintestinal cancers, with gastric cancer emerging as the most frequently diagnosed malignancy since 2020.

First-Time Seizure Is Linked to a Markedly Increased Short-Term Risk of Occult Cancer
Neurologycancer riskfirst-time seizure

First-Time Seizure Is Linked to a Markedly Increased Short-Term Risk of Occult Cancer

By MedXY|May 3, 2026

A nationwide Danish cohort study found that adults with a first-time seizure had substantially elevated 1-year risks of neurological and nonneurological cancers, with smaller but persistent excess risk over longer follow-up.

Quality of Breast Cancer Care and Patient Survival Show No Link to Hospital Safety-Net Burden
newsbreast cancerCare Quality

Quality of Breast Cancer Care and Patient Survival Show No Link to Hospital Safety-Net Burden

By MedXY|May 1, 2026

A major study reveals that safety-net hospitals—serving vulnerable Medicaid and uninsured patients—deliver breast cancer care and survival outcomes on par with other hospitals, challenging assumptions about quality disparities in resource-c

Danish Multicenter Study Finds a 15% ADNEX Threshold Best Balances Early Detection and Referral Burden for Adnexal Masses
newsIOTA ADNEXovarian cancer triage

Danish Multicenter Study Finds a 15% ADNEX Threshold Best Balances Early Detection and Referral Burden for Adnexal Masses

By MedXY|Aug 18, 2026

In a Danish multicenter cohort of adnexal masses, IOTA-based models outperformed RMI for routine triage. A 15% ADNEX threshold best balanced sensitivity and referral burden in non-tertiary care.

Prev
16 / 25
1…1415161718…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles